Apart from being involved in cancer development, progression, metastasis, and recurrence, CD147 has also been associated with resistance to multiple anti-cancer therapies such as Temozolomide (89), Cisplatin (90), Oxaliplatin (91), Biguanides (Metformin) (92), Doxorubicin (93), Ara-C (Cytarabine) (80), Gemcitabine (86), Paclitaxel (94), Epirubicin (95), Docetaxel (96), Vemurafenib (97), and Radiotherapy (48); exhibited in gliomas, carcinomas of the Larynx, lung, breast, gastric, liver, pancreas, colon, bladder, prostate, ovary, and cervical; melanoma, and lymphomas (Figure 2). Here, BSG is linked to melanoma.